Kura Oncology Inc (KURA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Troy E. Wilson |
| Employees: | 130 |
| Web site: | kuraoncology.com |
|
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130
(858) 500-8800
| |
-
Formally known as:
- KURA ONCOLOGY INC COM
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.
Please log in first to see chart